Alexander C. J. van Akkooi, MD, PhD, on Domatinostat Plus Avelumab for Merkel Cell Carcinoma

Posted: Friday, June 18, 2021

Alexander van Akkooi, MD, PhD, of The Netherlands Cancer Institute, discusses the ongoing phase II MERKLIN 2 study, being conducted across Europe and the United States, to investigate the efficacy and safety of the HDAC inhibitor domatinostat in combination with avelumab in patients with advanced unresectable/metastatic Merkel cell carcinoma progressing on anti–PD-L1 antibody therapy.